FDA Warning Letters and recent high-profile recalls indicate major cGMP deficiencies in many companies. One major failing is the lack of sufficient or targeted risk-based company-wide V&V planning.

Starting with a Master Validation Plan, evaluating its elements against ISO 14971 hazard analysis/risk management allows the development of meaningful product validations. The roles of different V&V protocols. How to employ equipment/process DQs, IQs, OQs, and PQs, or their equivalents per ASTM E2500, against a background of limited company resources (personnel, budget, time). A matrix simplifies “as-product”, “in-product”, process, and equipment, et al, software V&VT, assuring key FDA requirements are not overlooked. The QMS and 21 CFR Part 11 must also be considered.

Areas Covered in the Session:-

• Verification or Validation – Recent regulatory expectations
• The Master Validation Plan and its structure
• Product Validation – how it differs from process/equipment V&V
• Process / Equipment / Facility Validation – including FDA’s recent guidance
• When and How to use DQ, IQ, OQ, PQ, or their equivalents
• How to use Product Risk Management Tools (per ISO 14971 and ICH Q9)
• The 11 key documents for software validation
• Incorporating 21 CFR Part 11 requirements
• Suggested “test case” formats

Why You Should Attend:-

Verification and validation requirements have always been part of the US FDA’s GMPs. However, with increasing technology, both industry and regulatory agencies' expectations have increased.

Recent high-profile field problems indicate that V&V activities are not planned or carried out as completely as expected, are not documented in a top tier Master Validation Plan, and may not be fully utilizing the power of current risk management tools, as identified in ISO 14971. The FDA / ICH Q-series provide valuable insights for all regulated industries, not just pharma. The billions of dollars spent by the industry annually for V&V are not providing the product safety or efficacy seemingly promised. For most companies, the fixes are not rocket-science, but proper up-front V&V planning and execution, documented in a corporate MVP, and implemented by other V&V documents.

Who Should Attend:-

• Quality Departments
• Regulatory Affairs Departments
• R&D Departments
• Engineering Departments
• Production Departments
• Operations Departments
• Consultants